AZD0530
AZD0530 is a pharmaceutical drug with 8 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 7 completed trials
Phase Distribution
Phase Distribution
6
Early Stage
2
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
87.5%
7 of 8 finished
12.5%
1 ended early
0
trials recruiting
8
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
AZD0530 and Gemcitabine in Locally Advanced/Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease
AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer
AZD0530 Study 21 - Phase I Study in Patients With Solid Tumours
Phase I Study in Patients With Solid Tumours
Clinical Trials (8)
AZD0530 and Gemcitabine in Locally Advanced/Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease
AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer
AZD0530 Study 21 - Phase I Study in Patients With Solid Tumours
Phase I Study in Patients With Solid Tumours
Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours
Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel
Relative Bioavailability of Phase II and Phase III Formulations of AZD0530
All 8 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 8